Mithramycin has inhibitory effects on gliostatin and matrix metalloproteinase expression induced by gliostatin in rheumatoid fibroblast-like synoviocytes

References

• Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233–55.
   PubMed Web of Science ®Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6:75–92.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19.
   PubMed Web of Science ®Google Scholar
• Asai K, Nakanishi K, Isobe I, Eksioglu YZ, Hirano A, Hama K, et al. Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J Biol Chem. 1992;267:20311–16.
   PubMed Web of Science ®Google Scholar
• Asai K, Hirano T, Matsukawa K, Kusada J, Takeuchi M, Otsuka T, et al. High concentrations of immunoreactive gliostatin/platelet-derived endothelial cell growth factor in synovial fluid and serum of rheumatoid arthritis. Clin Chim Acta. 1993;218:1–4.
   PubMed Web of Science ®Google Scholar
• Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 1995;55:1687–90.
   PubMed Web of Science ®Google Scholar
• Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA. 1995;92:998–1002.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum. 1994;37:662–72.
   PubMed Web of Science ®Google Scholar
• Tanikawa T, Waguri-Nagaya Y, Kusabe T, Aoyama M, Asai K, Otsuka T. Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes. Rheumatol Int. 2007;27:553–9.
   PubMed Web of Science ®Google Scholar
• Waguri Y, Otsuka T, Sugimura I, Matsui N, Asai K, Moriyama A, et al. Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. Br J Rheumatol. 1997;36:315–21.
   PubMedGoogle Scholar
• Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saijo A, et al. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 2014;66:560–8.
   PubMed Web of Science ®Google Scholar
• Waguri-Nagaya Y, Otsuka T, Sugimura I, Matsui N, Asai K, Nakajima K, et al. Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees. Rheumatol Int. 2000;20:13–19.
   PubMed Web of Science ®Google Scholar
• Muro H, Waguri-Nagaya Y, Otsuka T, Matsui N, Asai K, Kato T. Serum gliostatin levels in patients with rheumatoid factor-negative and -positive rheumatoid arthritis and changes of these levels after surgical treatments. Clin Rheumatol. 2001;20:331–6.
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73.
   PubMed Web of Science ®Google Scholar
• Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000;59:455–61.
   PubMed Web of Science ®Google Scholar
• Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ, et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int. 2011;31:543–7.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999;58:691–7.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.
   PubMed Web of Science ®Google Scholar
• Muro H, Waguri-Nagaya Y, Mukofujiwara Y, Iwahashi T, Otsuka T, Matsui N, et al. Autocrine induction of gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) and GLS-induced expression of matrix metalloproteinases in rheumatoid arthritis synoviocytes. Rheumatology (Oxford). 1999;38:1195–202.
   PubMed Web of Science ®Google Scholar
• Lombó F, Menéndez N, Salas JA, Méndez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol. 2006;73:1–14.
   PubMed Web of Science ®Google Scholar
• Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest. 1991;88:1613–21.
   PubMed Web of Science ®Google Scholar
• Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci. 2011;31:6858–70.
   PubMed Web of Science ®Google Scholar
• Ikuta K, Waguri-Nagaya Y, Kikuchi K, Yamagami T, Nozaki M, Aoyama M, et al. The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes. Arthritis Res Ther. 2012;14:R87.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol. 1999;163:351–8.
   PubMed Web of Science ®Google Scholar
• Kusabe T, Waguri-Nagaya Y, Tanikawa T, Aoyama M, Fukuoka M, Kobayashi M, et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol Int. 2005;25:625–30.
   PubMed Web of Science ®Google Scholar
• Hirano T, Asai K, Matsukawa K, Kato T, Takeuchi M, Yonezawa M, et al. Establishment of an enzyme immunoassay system for gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF). Biochim Biophys Acta. 1993;1176:299–304.
   PubMed Web of Science ®Google Scholar
• Huang HC, Tsai LL, Tsai JP, Hsieh SC, Yang SF, Hsueh JT, et al. Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression. Tumour Biol. 2014;35:12139–49.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang Y, Huang Y, Xia X, Zhang J, Zhou Y, et al. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer. Carcinogenesis. 2014;35:442–51.
   PubMed Web of Science ®Google Scholar
• Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY, et al. Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer. 2014;14:276.
   PubMed Web of Science ®Google Scholar
• Kum YS, Kim KH, Park TI, Suh IS, Oh HK, Cho CH, et al. Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis. Biochem Biophys Res Commun. 2007;363:368–74.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38.
   PubMed Web of Science ®Google Scholar
• Klein K, Ospelt C, Gay S. Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther. 2012;14:227.
   PubMed Web of Science ®Google Scholar
• Wada TT, Araki Y, Sato K, Aizaki Y, Yokota K, Kim YT, et al. Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem Biophys Res Commun. 2014;444:682–6.
   PubMed Web of Science ®Google Scholar
• Araki Y, Wada TT, Aizaki Y, Sato K, Yokota K, Fujimoto K, et al. Histone methylation and STAT-3 differentially regulate interleukin-6-induced matrix metalloproteinase gene activation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatol. 2016;68:1111–23.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Sanyal S, Kulkarni KK, Jana K, Roy S, Das C, et al. Anticancer drug mithramycin interacts with core histones: an additional mode of action of the DNA groove binder. FEBS Open Bio. 2014;4:987–95.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci. 2004;24:10335–42.
   PubMed Web of Science ®Google Scholar
• Fang K, Koller CA, Brown N, Covington W, Lin JR, Ho DH. Determination of plicamycin in plasma by radioimmunoassay. Ther Drug Monit. 1992;14:255–60.
   PubMed Web of Science ®Google Scholar
• Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999;59:1911–96.
   PubMed Web of Science ®Google Scholar
• Rutkauskaite E, Zacharias W, Schedel J, Müller-Ladner U, Mawrin C, Seemayer CA, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2004;50:1448–56.
   PubMed Web of Science ®Google Scholar
• van Meurs J, van Lent P, Holthuysen A, Lambrou D, Bayne E, Singer I, et al. Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for stromelysin-1 in cartilage destruction. J Immunol. 1999;163:5633–9.
   PubMed Web of Science ®Google Scholar
• Singh A, Rajasekaran N, Hartenstein B, Szabowski S, Gajda M, Angel P, et al. Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis. Arthritis Res Ther. 2013;15:R222.
   PubMed Web of Science ®Google Scholar
• Xue M, McKelvey K, Shen K, Minhas N, March L, Park SY, et al. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology (Oxford). 2014;53:2270–9.
   PubMed Web of Science ®Google Scholar
• Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol. 2002;169:2643–7.
   PubMed Web of Science ®Google Scholar
• Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–44.
   PubMed Web of Science ®Google Scholar
• Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8:171–7.
   PubMedGoogle Scholar
• Fibach E, Bianchi N, Borgatti M, Prus E, Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood. 2003;102:1276–81.
   PubMed Web of Science ®Google Scholar
• Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res. 2006;34:1721–34.
   PubMed Web of Science ®Google Scholar
• Núñez LE, Nybo SE, González-Sabín J, Pérez M, Menéndez N, Braña AF, et al. A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. J Med Chem. 2012;55:5813–25.
   PubMed Web of Science ®Google Scholar